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Keywords: Cystic ﬁbrosis; Antifungal therapyAzole antifungal drugs such as itraconazole and voriconazole,
are commonly used for the treatment of isolates of Aspergillus, or
in combination with corticosteroids for the empiric treatment of
allergic bronchopulmonary aspergillosis (ABPA), in children
with cystic fibrosis (CF). Although the use of antifungals as part
of the treatment for ABPA is not reinforced by a plethora of large
randomised controlled trials, they are nevertheless recommended
by a number of national clinical guidelines [1,2]. However the
usefulness of these agents may be limited by the inability to reach
therapeutic levels [3]. The aim of this study was to measure blood
levels of itraconazole and voriconazole in children receiving
these drugs orally to assess whether therapeutic drug levels were
ever achieved.
This was a 2 year prospective study carried out in a single
paediatric CF specialist centre. We assessed consecutive patients
receiving azole antifungals who had been admitted to hospital, in
order to ensure adherence to the drug regimen at the time levels
were measured. We measured random itraconazole levels in 16
patients, with a median age of 14 years (range 9–16) on 26
occasions. Five patients were excluded due to: levels taken before
steady state reached (n=2) or not taken at all due to error (n=3).
We aimed for a therapeutic range of 5–15 mg/L (as per Regional
Mycology Laboratory, Manchester, www.mycologymanchester.
org/antifungal.html). The mean dose was 5.1 mg/kg/day (range
2.4–8.5), with all but one patient taking itraconazole in its capsule
form with coca-cola or orange juice to enhance absorption.
Twelve patients were taking concomitant acid suppressing drugs
e.g. omeprazole or ranitidine. The serum blood levels, measured
by bioassay, ranged from b0.8 mg/L (undetectable) to 7.5 mg/L,
with 20/26 (77%) samples having undetectable levels b0.8 mg/L.⁎ Corresponding author at: Department of Paediatric Respiratory Medicine,
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http://dx.doi.org/10.1016/j.jcf.2012.09.007Only 2/16 (12.5%) patients had levels within the therapeutic
range. Of these, one was taking the more effectively absorbed
liquid preparation and the other was inadvertently given double
her usual dose. As a consequence of these results we doubled our
initial itraconazole dose to 10 mg/kg/day in two divided doses
and preliminary data so far shows that 4/8 (50%) patients attained
therapeutic levels with the higher starting dose.
We also measured voriconazole trough levels in 8 in-patients,
with a median age of 13 years (range 12–16) on 18 occasions.
Six patients were excluded due to: levels taken at incorrect time
(not trough) or at an unrecorded time (could not be certain it was a
trough). We aimed for a therapeutic range of 1.3–5.7 mg/L. The
doses ranged from 200 to 400 mg/day. Therapeutic serum blood
levels, measured by HPLC, were attained in only 2/8 (25%)
patients. One patient had undetectable levels (b0.1 mg/L) on 3/3
occasions and one on 1/3 occasions.
Therapeutic drugmonitoring provides an objective measure of
the serum drug levels. This is particularly important in children
with CF given their altered handling of certain medicines [4].
Additionally, there is often a need to continue prescribing
interacting medicines to manage other facets of their disease e.g.
omeprazole, the effects of which reduce the absorption of
itraconazole. This is particularly relevant when we are using
medicines that have not been specifically tested in CF, and are
following dosing regimens tailored to a different patient
population.
The doses that we used were based on those recommended in
several clinical guidelines and according to manufacturer's
literature [1,2]. Despite this, according to the levels attained, it is
likely that we are underdosing our cohort of patients. One may
argue though that there is little evidence to link the ideal therapeutic
levels of these antifungals with outcomes in treatment of ABPA in
CF children. However given the paucity of randomised controlled
trials into antifungals in ABPA it may still be prudent to optimiseby Elsevier B.V. All rights reserved.
419Correspondencetherapy wherever possible by carrying out therapeutic drug
monitoring of these antifungals in children with CF. It is also
worth knowing that therapeutic itraconazole levels were reached
before considering second line drugs such as voriconazole,
especially considering their higher burden of side effects and cost.
Finally, it is important to ensure that therapeutic levels are
obtained in clinical trials to be certain that effectiveness has
been truly assessed. In a recent small Canadian trial of oral
itraconazole in children and adults with CF [5], blood levels
were assessed at the end of the trial in 14/18 subjects in the
active arm, and levels were in the therapeutic range in only 8/14
(57%) subjects, making the trial results less valid.
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